Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

2.

TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition.

Kim MJ, Park SA, Kim CH, Park SY, Kim JS, Kim DK, Nam JS, Sheen YY.

Cell Physiol Biochem. 2016;38(2):571-88. doi: 10.1159/000438651. Epub 2016 Feb 5.

3.

Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.

Naka K, Ishihara K, Jomen Y, Jin CH, Kim DH, Gu YK, Jeong ES, Li S, Krause DS, Kim DW, Bae E, Takihara Y, Hirao A, Oshima H, Oshima M, Ooshima A, Sheen YY, Kim SJ, Kim DK.

Cancer Sci. 2016 Feb;107(2):140-8. doi: 10.1111/cas.12849. Epub 2016 Jan 26.

4.

Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.

Krishnaiah M, Jin CH, Sheen YY, Kim DK.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5228-31. doi: 10.1016/j.bmcl.2015.09.058. Epub 2015 Sep 26.

PMID:
26483198
5.

Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.

Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, Lim W, Nam JS, Sheen YY.

Oncotarget. 2015 Nov 10;6(35):37526-43. doi: 10.18632/oncotarget.6063.

6.

EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.

Park SA, Kim MJ, Park SY, Kim JS, Lee SJ, Woo HA, Kim DK, Nam JS, Sheen YY.

Cell Mol Life Sci. 2015 May;72(10):2023-39. doi: 10.1007/s00018-014-1798-6. Epub 2014 Dec 9.

PMID:
25487606
7.

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.

Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY.

Cancer Lett. 2014 Aug 28;351(1):72-80. doi: 10.1016/j.canlet.2014.05.006. Epub 2014 Jun 2.

PMID:
24887560
8.

EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.

Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, Sheen YY.

Mol Cancer Ther. 2014 Jul;13(7):1704-16. doi: 10.1158/1535-7163.MCT-13-0903. Epub 2014 May 9.

9.

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK.

J Med Chem. 2014 May 22;57(10):4213-38. doi: 10.1021/jm500115w. Epub 2014 May 13.

PMID:
24786585
10.

4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Park HJ, Park SJ, Sheen YY, Kim DK.

Bioorg Med Chem. 2014 May 1;22(9):2724-32. doi: 10.1016/j.bmc.2014.03.022. Epub 2014 Mar 21.

PMID:
24704197
11.

Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy.

Sheen YY, Kim MJ, Park SA, Park SY, Nam JS.

Biomol Ther (Seoul). 2013 Sep 30;21(5):323-31. doi: 10.4062/biomolther.2013.072. Review.

12.

Green tea catechin leads to global improvement among Alzheimer's disease-related phenotypes in NSE/hAPP-C105 Tg mice.

Lim HJ, Shim SB, Jee SW, Lee SH, Lim CJ, Hong JT, Sheen YY, Hwang DY.

J Nutr Biochem. 2013 Jul;24(7):1302-13. doi: 10.1016/j.jnutbio.2012.10.005. Epub 2013 Jan 17.

PMID:
23333093
13.

High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2α.

Kim RJ, Park JR, Roh KJ, Choi AR, Kim SR, Kim PH, Yu JH, Lee JW, Ahn SH, Gong G, Hwang JW, Kang KS, Kong G, Sheen YY, Nam JS.

Cancer Lett. 2013 Jun 1;333(1):18-31. doi: 10.1016/j.canlet.2012.11.026. Epub 2012 Nov 19.

PMID:
23174107
14.

Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-a]-pyridin-6-yl)thiazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

Krishnaiah M, Jin CH, Sreenu D, Subrahmanyam VB, Rao KS, Son DH, Park HJ, Kim SW, Sheen YY, Kim DK.

Eur J Med Chem. 2012 Nov;57:74-84. doi: 10.1016/j.ejmech.2012.09.011. Epub 2012 Sep 20.

PMID:
23047226
15.

Anti-Cancer Effect of 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide in MCF-7 Human Breast Cancer.

Min KN, Joung KE, Kim DK, Sheen YY.

Environ Health Toxicol. 2012;27:e2012010. doi: 10.5620/eht.2012.27.e2012010. Epub 2012 Apr 25.

16.

Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer.

Min KN, Joung KE, Kim DK, Sheen YY.

Biomol Ther (Seoul). 2012 May;20(3):313-9. doi: 10.4062/biomolther.2012.20.3.313.

17.

Identification of EBP50 as a specific biomarker for carcinogens via the analysis of mouse lymphoma cellular proteome.

Lee YJ, Choi IK, Sheen YY, Park SN, Kwon HJ.

Mol Cells. 2012 Mar;33(3):309-16. doi: 10.1007/s10059-012-2280-7. Epub 2012 Feb 28.

18.

Moesin is a biomarker for the assessment of genotoxic carcinogens in mouse lymphoma.

Lee YJ, Choi IK, Sheen YY, Park SN, Kwon HJ.

Mol Cells. 2012 Feb;33(2):203-10. doi: 10.1007/s10059-012-2271-8. Epub 2012 Jan 26.

19.

Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer.

Joung KE, Min KN, Kim DK, Sheen YY.

Biomol Ther (Seoul). 2012 Jan;20(1):81-8. doi: 10.4062/biomolther.2012.20.1.081.

20.

Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Mohan AV, Park CY, Son JY, Sheen YY, Kim DK.

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6049-53. doi: 10.1016/j.bmcl.2011.08.064. Epub 2011 Aug 22.

PMID:
21911290
21.

EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.

Park CY, Son JY, Jin CH, Nam JS, Kim DK, Sheen YY.

Eur J Cancer. 2011 Nov;47(17):2642-53. doi: 10.1016/j.ejca.2011.07.007. Epub 2011 Aug 16.

PMID:
21852112
23.

Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

Jin CH, Sreenu D, Krishnaiah M, Subrahmanyam VB, Rao KS, Nagendra Mohan AV, Park CY, Son JY, Son DH, Park HJ, Sheen YY, Kim DK.

Eur J Med Chem. 2011 Sep;46(9):3917-25. doi: 10.1016/j.ejmech.2011.05.063. Epub 2011 Jun 22.

PMID:
21696866
24.

Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.

Jin CH, Krishnaiah M, Sreenu D, Rao KS, Subrahmanyam VB, Park CY, Son JY, Sheen YY, Kim DK.

Bioorg Med Chem. 2011 Apr 15;19(8):2633-40. doi: 10.1016/j.bmc.2011.03.008. Epub 2011 Mar 22.

PMID:
21435890
25.

Melphalan modulates the expression of E7-specific biomarkers in E7-Tg mice.

Kim EJ, Kim H, Lee S, Kang JW, Lee DH, Choi HS, Kim JM, Yang Y, Sheen YY, Park SN, Yoon DY.

Anticancer Res. 2010 Jul;30(7):2773-83.

PMID:
20683012
26.

Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.

Kim DK, Lee YI, Lee YW, Dewang PM, Sheen YY, Kim YW, Park HJ, Yoo J, Lee HS, Kim YK.

Bioorg Med Chem. 2010 Jun 15;18(12):4459-67. doi: 10.1016/j.bmc.2010.04.071. Epub 2010 Apr 28.

PMID:
20472445
27.
28.

The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles.

Cho M, Cho WS, Choi M, Kim SJ, Han BS, Kim SH, Kim HO, Sheen YY, Jeong J.

Toxicol Lett. 2009 Sep 28;189(3):177-83. doi: 10.1016/j.toxlet.2009.04.017. Epub 2009 May 3.

PMID:
19397964
29.

Expression of human liver 3, 4-catechol estrogens UDP-Glucuronosyltransferase cDNA in COS 1 cells.

Ahn MR, Owens IS, Sheen YY.

Arch Pharm Res. 1997 Oct;20(5):465-70. doi: 10.1007/BF02973941.

PMID:
18982491
30.

Cloning and expression of human liver UDP-glucuronosyltransferase cDNA, UDPGTh2.

Dong M, Owens IS, Sheen YY.

Arch Pharm Res. 1997 Oct;20(5):459-64. doi: 10.1007/BF02973940.

PMID:
18982490
31.

Comparison of glucuronidating activity of two human cDNAs, UDPGTh1 and UDPGTh2.

Kim SS, Owens IS, Sheen YY.

Arch Pharm Res. 1997 Oct;20(5):454-8. doi: 10.1007/BF02973939.

PMID:
18982489
32.

Stimulation of troutCYP1A gene expression in mouse HEPA-1 cells by 3-methylcholanthrene.

Lee SY, Sheen YY.

Arch Pharm Res. 1997 Oct;20(5):404-9. doi: 10.1007/BF02973930.

PMID:
18982480
33.

Antiestrogen interaction with estrogen receptors and additional antiestrogen binding sites in human breast cancer MCF-7 cells.

Ahn MR, Sheen YY.

Arch Pharm Res. 1997 Dec;20(6):579-85. doi: 10.1007/BF02975215.

PMID:
18982263
34.

Antiestrogen, trans-tamoxifen modulation of human breast cancer cell growth.

Lee HO, Sheen YY.

Arch Pharm Res. 1997 Dec;20(6):572-8. doi: 10.1007/BF02975214.

PMID:
18982262
35.

Estrogen modulation of human breast cancer cell growth.

Lee HO, Sheen YY.

Arch Pharm Res. 1997 Dec;20(6):566-71. doi: 10.1007/BF02975213.

PMID:
18982261
36.

Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells.

Lee GT, Hong JH, Mueller TJ, Watson JA, Kwak C, Sheen YY, Kim DK, Kim SJ, Kim IY.

J Urol. 2008 Dec;180(6):2660-7. doi: 10.1016/j.juro.2008.08.008. Epub 2008 Oct 31.

PMID:
18951571
37.

Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1.

Yu JY, Lee JJ, Lim Y, Kim TJ, Jin YR, Sheen YY, Yun YP.

J Pharmacol Sci. 2008 May;107(1):90-8.

38.

Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor.

Kim YW, Kim YK, Kim DK, Sheen YY.

Xenobiotica. 2008 May;38(5):451-64. doi: 10.1080/00498250701871121 .

PMID:
18421620
39.

YSK2821, a newly synthesized indoledione derivative, inhibits cell proliferation and cell cycle progression via the cell cycle-related proteins by regulating phosphatidylinositol-3 kinase cascade in vascular smooth muscle cells.

Seo JM, Kim TJ, Jin YR, Han HJ, Ryu CK, Sheen YY, Kim DW, Yun YP.

Eur J Pharmacol. 2008 May 31;586(1-3):74-81. doi: 10.1016/j.ejphar.2008.02.076. Epub 2008 Mar 4.

PMID:
18402936
40.

Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.

Kim YW, Kim YK, Lee JY, Chang KT, Lee HJ, Kim DK, Sheen YY.

Xenobiotica. 2008 Mar;38(3):325-39. doi: 10.1080/00498250701781924 .

PMID:
18274960
41.

Asymmetric synthesis of cyclopropyl-fused 2'-C-methylcarbanucleosides as potential anti-HCV agents.

Jeong LS, Lee JA, Kim HO, Tosh DK, Moon HR, Lee SJ, Lee KM, Sheen YY, Chun MW.

Nucleosides Nucleotides Nucleic Acids. 2007;26(8-9):1021-4.

PMID:
18058529
42.

Differential effect of 7,12-dimethylbenz[a]anthracene on human and mouse CYP1B1 from livers of castrated transgenic mice.

Hwang DY, Chae KR, Kim CK, Kim BG, Shim SB, Jee SW, Lee SH, Sin JS, Jang MK, Seo SJ, Kim MS, Cho JS, Sheen YY, Choi SY, Kim YK.

Int J Toxicol. 2007 Jan-Feb;26(1):71-80.

PMID:
17365149
43.

DRE-CALUX bioassay in comparison with HRGC/MS for measurement of toxic equivalence in environmental samples.

Joung KE, Chung YH, Sheen YY.

Sci Total Environ. 2007 Jan 1;372(2-3):657-67. Epub 2006 Dec 5.

PMID:
17156822
44.
45.

Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.

Joung KE, Min KN, An JY, Kim DK, Kong G, Sheen YY.

Cancer Res. 2006 May 15;66(10):5394-402.

46.

Tau and GSK3beta dephosphorylations are required for regulating Pin1 phosphorylation.

Min SH, Cho JS, Oh JH, Shim SB, Hwang DY, Lee SH, Jee SW, Lim HJ, Kim MY, Sheen YY, Lee SH, Kim YK.

Neurochem Res. 2005 Aug;30(8):955-61.

PMID:
16258844
47.

Stereoselective synthesis of 3-hydroxymethyl-D-cyclopentenone, the versatile intermediate for the synthesis of carbocyclic nucleosides.

Choi WJ, Moon HR, Kim HO, Ko YM, Kim HJ, Lee JA, Lee KM, Yun MK, Shin DH, Chun MW, Sheen YY, Kim K, Jeong LS.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):611-3.

PMID:
16247998
48.

NSE-controlled carboxyl-terminus of APP gene over-expressing in transgenic mice induces altered expressions in behavior, Abeta-42, and GSK3beta binding proteins.

Lim HJ, Cho JS, Oh JH, Shim SB, Hwang DY, Jee SW, Lee SH, Sheen YY, Lee SH, Kim YK.

Cell Mol Neurobiol. 2005 Aug;25(5):833-50.

PMID:
16133937
49.

An in vivo bioassay for detecting antiandrogens using humanized transgenic mice coexpressing the tetracycline-controlled transactivator and human CYP1B1 gene.

Hwang DY, Cho JS, Oh JH, Shim SB, Jee SW, Lee SH, Seo SJ, Kang HG, Sheen YY, Lee SH, Kim YK.

Int J Toxicol. 2005 May-Jun;24(3):157-64.

PMID:
16040568
50.

Comprehensive analysis of differential gene expression profiles on carbon tetrachloride-induced rat liver injury and regeneration.

Chung H, Hong DP, Jung JY, Kim HJ, Jang KS, Sheen YY, Ahn JI, Lee YS, Kong G.

Toxicol Appl Pharmacol. 2005 Aug 1;206(1):27-42. Epub 2004 Dec 24.

PMID:
15963342

Supplemental Content

Loading ...
Support Center